Curated News
By: NewsRamp Editorial Staff
August 24, 2026

VERAXA Advances VXA-222 Cancer Program with OmniAb Collaboration

Discuss on LinkedInDiscuss on X, formerly TwitterDiscuss on SubstackDiscuss on TelegramParticipate in discussion on BlueskyParticipate in discussion on MastodonView history of this news story on GitHub
Original Source

TLDR

  • VERAXA advances VXA-222, gaining edge in cancer therapy race with novel dual-targeting bispecific antibody-drug conjugate.
  • VXA-222 uses AND-gate logic to recognize two tumor antigens simultaneously, triggering payload delivery only when both are present.
  • VERAXA's targeted cancer therapy aims to improve patient outcomes by reducing off-target effects, promising a better tomorrow.
  • VERAXA's BiTAC platforms expand its pipeline, with new patents protecting antibody conjugation and payload technologies.

Impact - Why it Matters

This news matters because it signals significant progress in the development of a novel cancer therapy that could offer a more targeted and effective treatment option. VERAXA's VXA-222, with its dual-antigen recognition, has the potential to improve patient outcomes while reducing side effects compared to traditional therapies. For investors, this milestone indicates the company's execution capability and could influence the valuation of VRXA stock. For the broader biotech industry, it showcases the promise of innovative antibody engineering approaches in the fight against cancer.

Summary

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has advanced its VXA-222 bispecific antibody-drug conjugate program to the next development stage following the completion of the initial phase of its collaboration with OmniAb. The company will now engineer the final VXA-222 candidate using its own antibody engineering, linker, and conjugation technologies, and conduct preclinical validation to determine next steps. VXA-222 employs an innovative “AND-gate” approach that requires the simultaneous recognition of two tumor-associated antigens before delivering its therapeutic payload, potentially increasing specificity and reducing off-target effects. This milestone is part of VERAXA’s broader strategy to build a diversified oncology pipeline spanning bispecific T-cell engagers, ADCs, and other engineered antibody formats.

In parallel, VERAXA has filed its first patents related to its BiTAC-TCE and BiTAC-ADC platforms, expanding intellectual property protection around antibody conjugation and payload technologies. This robust IP strategy underscores the company’s commitment to innovation and positions it to capitalize on its proprietary platforms. The news was reported by Yahoo Finance and further detailed in a Read More>> article, with updates available in the company’s newsroom at https://ibn.fm/VRXA. BillionDollarClub, a specialized communications platform, highlighted this development, emphasizing VERAXA’s progress in the competitive oncology landscape.

The advancement of VXA-222 is a significant step for VERAXA as it moves from discovery to preclinical development, potentially bringing a novel cancer therapy closer to clinical trials. The company’s focus on dual-antigen recognition and its expanding patent portfolio demonstrate a strategic approach to creating differentiated therapies. Investors and industry observers will be watching closely as VERAXA continues to execute on its development plans and strengthen its position in the biotech sector.

Source Statement

This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, VERAXA Advances VXA-222 Cancer Program with OmniAb Collaboration

Blockchain registration record for this content